AUS
NZ
UK
CA
USA
IND
Healthcare
Why Is Emyria Expanding Into Global Drug Services Now?
April 20, 2026 03:22 PM AEST| By SamEmyria introduces a global services platform targeting drug sponsors, unlocking new revenue opportunities while addressing growing demand for clinical delivery in advanced mental health therapies worldwide.
Why Is (ASX:RAD) Drawing Attention After Clinical Update?
April 20, 2026 03:14 PM AEST| By SamRadiopharm Theranostics shares gain attention as early trial data highlights tumour targeting and safety profile, marking a notable step in its oncology research journey.
Could This New Platform Redefine Global Clinical Trials?
April 20, 2026 02:24 PM AEST| By SamEmyria launches a global clinical platform to connect drug sponsors with scalable infrastructure, aiming to accelerate complex therapy trials and improve patient access worldwide.
Why ASX All Ords Stock OCC Draws Market Focus?
April 20, 2026 12:09 PM AEST| By SamOrthocell highlights strong quarterly activity with Remplir rollout expansion in the US, reflecting healthcare innovation and regenerative medicine developments within ASX All Ords.
This Healthcare ASX 300 Stock Just Dropped After Record High
April 20, 2026 11:59 AM AEST| By SamPro Medicus reflects movement after record highs, highlighting healthcare technology trends and trading activity across ASX 300 and broader market indices.
All Ordinaries Healthcare Update as 4DMedical Gains Entry
April 20, 2026 11:35 AM AEST| By Sam4DMedical’s inclusion in the ASX benchmark highlights healthcare sector participation, reflecting evolving index composition and the role of medical technology within the Australian market.
ASX 300 Healthcare Play: Why Mesoblast Is Back in Focus
April 20, 2026 10:40 AM AEST| By SamMesoblast gains renewed attention after clinical progress and early commercial traction, strengthening its position within ASX 300 healthcare stocks and highlighting its evolving long-term growth narrative.
Mesoblast (ASX:MSB; NASDAQ:MESO) Accelerates Growth Strategy with CAR Tech and Commercial Momentum
April 20, 2026 04:05 AM AEST| By Team Kalkine MediaHighlights,Mesoblast advances its platform with the acquisition of CAR technology for MSC therapies.,The company has reported Ryoncil® revenue approaching US$100 million since launch.,CAR-MSC approach aims to enhance tissue targeting and treatment po...
Mesoblast (ASX:MSB) Drives ASX 200 Healthcare Buzz?
April 20, 2026 03:11 AM AEST| By SamMesoblast (ASX:MSB) gains attention following regulatory progress, highlighting biotechnology sector developments and healthcare participation across ASX indices.
Healthcare Sector Movement Drives ASX All Ords Attention
April 17, 2026 11:58 AM AEST| By SamCareteq reflects market valuation movement within the digital health sector, highlighting shareholder positioning and participation across ASX All Ords.
Is Orthocell (ASX:OCC) Expanding Its Role in ASX All Ordinaries Biotech Sector?
April 17, 2026 11:39 AM AEST| By SamOrthocell completes a Remplir procedure in a US military hospital network, highlighting clinical deployment and biotechnology sector participation within ASX All Ordinaries.
ASX 200 Healthcare Sector Sees Rising Market Focus
April 17, 2026 11:27 AM AEST| By SamASX healthcare sector activity highlights market participation and corporate developments, reflecting integration of biotechnology and pharmaceutical companies across major indices.
ASX 300 Insight: Why Oneview Is Expanding CDIs?
April 17, 2026 10:47 AM AEST| By SamOneview Healthcare has expanded its CDI base through an ASX quotation, improving liquidity and accessibility while continuing to support its growth in digital healthcare solutions and patient engagement platforms.
ASX 300 Update: What’s Driving Firebrick Pharma’s Share Move?
April 17, 2026 10:39 AM AEST| By SamFirebrick Pharma has expanded its share base through an ASX quotation, enhancing liquidity and funding flexibility while shifting focus toward execution and development across its biotechnology pipeline.
Can BlinkLab’s Fresh Capital Drive Its Next Big Break?
April 16, 2026 05:06 PM AEST| By SamBlinkLab advances autism and ADHD diagnostics through funding, clinical trials, and real-world deployment, strengthening its digital healthcare platform and regulatory progress.
Is (ASX:BB1) Entering a New Phase in Digital Diagnostics?
April 16, 2026 03:33 PM AEST| By SamBlinkLab advances digital diagnostics with new funding, supporting clinical trials, regulatory expansion, and global deployment of its smartphone-based neurodevelopmental screening platforms.
ASX 100 Healthcare Giant: Why COH Shares Are Under Spotlight
April 16, 2026 10:04 AM AEST| By SamCochlear shares are under focus after a pullback, with healthcare resilience, global demand, and valuation dynamics shaping its outlook as a key ASX 100 medical technology company.
Is Lumos Diagnostics (ASX:LDX) Shaping ASX All Ordinaries Healthcare Landscape?
April 15, 2026 06:04 PM AEST| By SamLumos Diagnostics outlines reporting plans and investor engagement while advancing its share purchase plan, reflecting continued activity within the healthcare diagnostics sector.
All Ordinaries Spotlight: Orthocell Expands Remplir Access
April 15, 2026 01:06 PM AEST| By SamOrthocell expanded access to US military and veterans hospitals, advancing Remplir distribution and strengthening its presence in the global healthcare sector.
SHL Under Pressure: Hidden Opportunity in ASX 100 Healthcare?
April 15, 2026 10:41 AM AEST| By SamSonic Healthcare’s valuation and global presence highlight a defensive yet growth-oriented profile, with healthcare demand stability and international expansion shaping its outlook despite recent share price weakness.
Advertise your brand on Kalkine Media